Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 52-Week High – Should You Buy?

Posted by Francis Steltz on Jun 23rd, 2026

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $40.26 and last traded at $40.2850, with a volume of 5890990 shares trading hands. The stock had previously closed at $40.18.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CNTA shares. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $35.00 to $42.00 in a report on Monday, April 20th. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price objective for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $41.33.

Read Our Latest Stock Analysis on Centessa Pharmaceuticals

Centessa Pharmaceuticals Trading Up 0.4%

The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $6.24 billion, a price-to-earnings ratio of -22.54 and a beta of 1.11. The business has a 50 day simple moving average of $39.68 and a 200-day simple moving average of $31.35.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the sale, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CNTA. Foresite Capital Management VI LLC lifted its position in Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after buying an additional 60,640 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Centessa Pharmaceuticals by 1,017.7% in the fourth quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after acquiring an additional 240,039 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter worth $5,999,000. Cinctive Capital Management LP purchased a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $2,246,000. Finally, Avoro Capital Advisors LLC raised its stake in shares of Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.